Abstract
Boehringer Ingelheim is involved in the manufacturing and marketing of human pharmaceuticals (prescription medicines, consumer health care products), products for industrial customers (chemicals and biopharmaceuticals) and animal health. This report provides a full review of the company's activities together with sales forecasts for key products to 2010.
Boehringer Ingelheim GmbH is the world's largest private pharmaceutical enterprise, encompasses more than 152 affiliates in 45 countries, and employing over 34,000 people. The company's activities are concentrated on two businesses: Human Pharmaceuticals and Animal Health.
Within the Prescription Medicines division, BI markets products in the following therapeutic areas: Respiratory, Cardiovascular, Immunology and Inflammation, Urology, Central Nervous System and Virology. Research and development is focused on developing treatments in the following fields: Respiratory, Cardiovascular, Immunology and Inflammation, Central Nervous System, Virology, Metabolic and Oncology.
Current Growth Drivers
Three of BI's current major products are forecast by Espicom to have sales in excess of EUR 1 billion by 2010, forming the foundations of short to medium growth in the prescription pharmaceutical sector.
- Spiriva (tiotropium bromide) is a novel, once-daily, inhaled treatment for chronic obstructive pulmonary disease.
- Micardis (telmisartan) is an angiotensin-II receptor blocker for the once-daily treatment of hypertension.
- Mobic (meloxicam) is a non-steroidal anti-inflammatory drug for the treatment of rheumatoid arthritis and osteoarthritis.
Table of Contents
Principal Operating Results
Latest Results
EXECUTIVE SUMMARY
- Introduction
- Current Growth Drivers
- Key Late-Stage Products
- Financial Performance 2005
- Sales and Market Position
- Income
- Expenditure
- Capital Expenditure
- R&D Expenditure
- Divisional Performance
- Sales By Business Area
- Geographic Performance
- Sales By Destination
- Company Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Discontinued Agreements
- Abbott
- 1st August 2005
- Medivir AB
- 15th March 2005
- NeuroSearch A⁄S
- 25th January 2006
- Employees
- Employees By Function
- Product ⁄ R&D Overview
- Key Products
- Recent Product Launches
- Recent Product Approvals
- R&D Strategy
- Key R&D Projects
- R&D Pipeline Overview
- Discontinued R&D projects
- Bivatuzumab
- MIV-310
- NS2330
- Sales Forecasts
- Key Products
- Conclusions
PRODUCT PORTFOLIO ⁄ RESEARCH & DEVELOPMENT
- Major Products, Therapeutic Areas and Sales
- R&D Pipeline
- Respiratory - Products
- Major Launched Products
- Combivent
- Sales
- Key Markets⁄Indications
- Competitor Products
- Sales Forecast
- Spiriva
- Sales
- Key Markets⁄Indications
- Further Development
- Competitor Products
- Sales Forecast
- Respiratory - R&D
- BIIL 284
- Respiratory - Summary
- Growth Potential
- Limiting Factors
- Cardiovascular - Products
- Major Launched Products
- Sales
- Key Markets⁄Indications
- Further Development
- Competitor Products
- Sales Forecast
- Clinical Trial Results - Stroke
- Micardis
- Sales
- Key Markets⁄Indications
- Further Development
- Competitor Products
- Patents
- Sales Forecast
- Clinical Trial Results - Chronic Kidney Disease
- Clinical Trial Results - Comparative Studies
- Clinical Trial Results - Metabolic Effects
- Others
- Major Launched Products
- Cardiovascular - R&D
- BIBR 1048
- BIII 890
- Rendix
- Cardiovascular - Summary
- Growth Potential
- Limiting Factors
- Immunology and Inflammation - Products
- Major Launched Products
- Mobic
- Sales
- Key Markets⁄Indications
- Sales Forecast
- Immunology and Inflammation - R&D
- BIBR 796
- Immunology and Inflammation - Summary
- Urology - Products
- Major Launched Products
- Flomax⁄Alna
- Sales
- Key Markets⁄Indications
- Competitor Products
- Safety Issues
- Patents⁄Licensees
- Sales Forecast
- Urology - R&D
- KUC 7483
- Urology - Summary
- Central Nervous System - Products
- Major Launched Products
- Sifrol⁄Mirapex⁄Mirapexin
- Sales
- Key Markets⁄Indications
- Further Development
- Competitor Products
- Safety Issues
- Patents
- Generic Competition⁄Lawsuits
- Sales Forecast
- Clinical Trial Results - Restless Leg Syndrome
- Cymbalta⁄Xeristar
- Key Markets⁄Indications
- Further Development
- Competitor Products
- Central Nervous System - R&D
- BIBN 4096
- Flibanserin (BIMT 17)
- Central Nervous System - Summary
- Growth Potential
- Limiting Factors
- Virology - Products
- Major Launched Products
- Aptivus
- Key Markets⁄Indications
- Further Development
- Compassionate Programmes
- Competitor Products
- Clinical Trial Results - RESIST
- Clinical Trial Results - Treatment Naive Patients
- Viramune
- Sales
- Key Markets⁄Indications
- Further Development
- Competitor Products
- Safety Issues
- Patents
- Generic Competition
- Sales Forecast
- Virology - R&D
- BILN 2061
- BILR-355
- Virology - Summary
- Growth Potential
- Limiting Factors
- Metabolic - R&D
- Metabolic - Summary
- Oncology - R&D
- MT201
- Oncology - Summary
APPENDIX 1 - FINANCIAL PERFORMANCE
- Full Year Results 2005
APPENDIX 2 - KEY AGREEMENTS
- AbGenomics Corporation
- 6th June 2005
- Astellas Pharma Inc
- 24th January 2002
- 16th August 2004
- Bayer
- 15th August 2002
- Biolipox AB
- 14th November 2005
- Eli Lilly
- 5th December 2002
- 15th February 2006
- Evotec AG
- 8th September 2004
- 7th June 2005
- 3rd November 2005
- 1st January 2006
- 10th March 2006
- Five Prime Therapeutics
- 25th March 2006
- Galapagos PLC
- 8th February 2000
- 16th January 2006
- GlaxoSmithKline
- 13th March 1998
- 12th July 2004
- ImmunoGen Inc
- 28th November 2001
- 15th October 2002
- 9th February 2005
- Kissei Pharmaceutical Co Ltd
- 29th November 2002
- Medarex Inc
- 14th June 2005
- Micromet AG
- 25th February 2004
- MorphoSys AG
- 25th February 2003
- 18th November 2003
- 16th August 2004
- 18th March 2005
- Novosom AG
- 16th January 2006
- Pfizer
- 28th January 2000
- 11th April 2001
- January 2004
- TeGenero AG
- 17th November 2003
- 20th March 2006
- 25th May 2006
- Therion Biologics Corporation
- 17th September 2002
APPENDIX 3 - INFRASTRUCTURE
- Research and Development Facilities
- Manufacturing Facilities
- Germany
- Austria
- North America
APPENDIX 4 - KEY PHARMACEUTICAL SUBSIDIARIES ⁄ JOINT VENTURES
- Subsidiaries
- Europe
- North America
- South America
- Rest of the world
- Joint Ventures
